Back to results
US 12,576,055 B2Granted
Disease detection and treatment based on trimethyl-lysine levels
AssigneeThe Cleveland Clinic Foundation
InventorsStanley L. Hazen, Zeneng Wang, Xinmin S. Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to systems, kits, and methods for identifying subjects with increased levels of N6-trimethyl-lysine (TML) or the combination of TML and trimethylamine-n-oxide (TMAO), as well as methods of determining risk of disease (e.g., kidney disease or heart failure) based on such levels. In certain embodiments, subjects with elevated TML, or TML and TMAO are treated with a therapeutic (e.g., one that inhibits the TMA/FMO3/TMAO pathway).
Claims3
A method of treating chronic kidney disease comprising:
- a) identifying a subject as having chronic kidney disease based on:
- i) having increased levels of N6-trimethyl-lysine (TML) compared to a control level, or having increased levels of TML and trimethylamine-n-oxide (TMAO) compared to control levels, and
- b) treating said subject with a first agent or first procedure that inhibits the TMA/FMO3/TMAO pathway.
Dependencies are inferred from the claim text.